Gufic Biosciences secures NMPA approval to market Prilocaine (API) in China
Gufic Biosciences has received approval from the National Medical Products Administration (NMPA) in China for its product, Prilocaine (API), an amide-type local anesthetic. The approval will aid in the commercialization of Prilocaine in China, opening up new opportunities in the Chinese market for Gufic. Prilocaine, which shares a similar clinical profile to lidocaine, is used […]